{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:52:10Z","timestamp":1762033930197,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jpba.2022.114862","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:45:39Z","timestamp":1654083939000},"page":"114862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Structural elucidation of major degradation products of milbemycin oxime drug substance using LC-MS and NMR"],"prefix":"10.1016","volume":"217","author":[{"given":"Sarju","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu M.","family":"Rustum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.114862_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7164\/antibiotics.41.519","article-title":"LL-F28249 antibiotic complex: a new family of antiparasitic macrocyclic lactones","volume":"41","author":"Carter","year":"1988","journal-title":"J. Antibiot."},{"key":"10.1016\/j.jpba.2022.114862_bib2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.7164\/antibiotics.33.1120","article-title":"Milbemycins, a new family of macrolide antibiotics: fermentation, isolation and physico-chemical properties","volume":"33","author":"Takiguchi","year":"2006","journal-title":"J. Antibiot."},{"key":"10.1016\/j.jpba.2022.114862_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0304-4017(94)00743-V","article-title":"Structure and activity of avermectins and milbemycins in animal health","volume":"59","author":"Shoop","year":"1995","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.jpba.2022.114862_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00937095","article-title":"In vitro effects of milbemycin oxime: mechanism of action againstAngiostrongylus cantonensis and Dirofilaria immitis","volume":"78","author":"Lee","year":"1992","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.jpba.2022.114862_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2307\/3283936","article-title":"The mechanism of action of avermectins in caenorhabditis elegans: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity","volume":"81","author":"Arena","year":"1995","journal-title":"J. Parasitol."},{"key":"10.1016\/j.jpba.2022.114862_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1039\/np9860300087","article-title":"Avermectins and milbemycins","volume":"3","author":"Davies","year":"1986","journal-title":"Nat. Prod. Rep."},{"year":"2002","series-title":"Macrocyclic Lactones In Antiparasitic Therapy","author":"Vercruysse","key":"10.1016\/j.jpba.2022.114862_bib7"},{"key":"10.1016\/j.jpba.2022.114862_bib8","first-page":"3108","article-title":"Development and validation of stability indicating HPLC method for simultaneous estimation of milbemycin oxime and praziquantel from bulk and marketed formulation","volume":"11","author":"Toranmal","year":"2019","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.jpba.2022.114862_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10337-021-04028-9","article-title":"Development and validation of a stability-indicating HPLC method for assay of milbemycin oxime and estimation of its related compounds","volume":"84","author":"Huang","year":"2021","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2022.114862_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/chromsci\/bmt142","article-title":"An LC-MS method for determination of milbemycin oxime in dog plasma","volume":"52","author":"Xu","year":"2014","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2022.114862_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jvp.12332","article-title":"The intravenous and oral pharmacokinetics of afoxolaner and milbemycin oxime when used as a combination chewable parasiticide for dogs","volume":"40","author":"Letendre","year":"2017","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2022.114862_bib12","unstructured":"European Pharmacopoeia 10.8. Milbemycin Oxime for Veterinary Use. Accessed 23 Dec 2021."},{"key":"10.1016\/j.jpba.2022.114862_bib13","unstructured":"ICH, Impurities in new drug substances Q3A (R2) (2006) guidelines. Accessed 15 Oct 2021."},{"key":"10.1016\/j.jpba.2022.114862_bib14","unstructured":"ICH, Impurities in new drug products Q3B (R2)(2006) guidelines. Accessed 15 Oct 2021."},{"key":"10.1016\/j.jpba.2022.114862_bib15","unstructured":"ICH, Validation of Analytical Procedures: Text and Methodology Q2(R1) (2005) guidelines. Accessed 15 Oct 2021."},{"key":"10.1016\/j.jpba.2022.114862_bib16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/1097-0231(20000730)14:14<1260::AID-RCM20>3.0.CO;2-#","article-title":"Mass spectrometry of Avermectins: structural determination of two new derivatives of Ivermectin B1a","volume":"14","author":"Gianelli","year":"2000","journal-title":"Rapid. Commun. Mass. Sp."},{"key":"10.1016\/j.jpba.2022.114862_bib17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/jms.343","article-title":"Determination of ivermectin B1a in animal plasma by liquid chromatography combined with electrospray ionization mass spectrometry","volume":"37","author":"Croubels","year":"2002","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2022.114862_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/jms.1085","article-title":"Tandem mass spectra of ammonium adducts of monosaccharides: differentiation of diastereomers","volume":"41","author":"Madhusudanan","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2022.114862_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/157341212803341717","article-title":"Separation and identification of degradation products in abamectin formulation using LC, LTQ FT-MS, H\/D exchange and NMR","volume":"8","author":"Awasthi","year":"2012","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.jpba.2022.114862_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1021\/jf00082a039","article-title":"Base-catalyzed isomerization of avermectins","volume":"36","author":"Pivnichny","year":"1988","journal-title":"J. Agr. Food Chem."},{"key":"10.1016\/j.jpba.2022.114862_bib21","unstructured":"B. W. Steven, A. M. Karen, R. A. Robert, Pharmaceutical stress testing: predicting drug degradation, Pinehurst, North Carolina, USA: Informa Healthcare, 2011."},{"key":"10.1016\/j.jpba.2022.114862_bib22","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00216-012-6393-9","article-title":"Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H\/D exchange and NMR","volume":"404","author":"Awasthi","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2022.114862_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0731-7085(96)01877-8","article-title":"Stability studies and high-performance liquid chromatographic procedures for L-648,548 and its major degradates in an animal health formulation","volume":"15","author":"Faulkner","year":"1997","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.114862_bib24","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1021\/acs.jnatprod.9b00524","article-title":"Spontaneous stereoselective oxidation of crystalline avermectin B1a to Its C-8a-(S)-hydroperoxide","volume":"82","author":"Gli\u0144ski","year":"2019","journal-title":"J. Nat. Prod."},{"year":"2012","series-title":"Organic Chemistry of Drug Degradation","author":"Li","key":"10.1016\/j.jpba.2022.114862_bib25"},{"key":"10.1016\/j.jpba.2022.114862_bib26","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1021\/cr0104375","article-title":"Cis\u2212trans isomerization of organic molecules and biomolecules: implications and applications","volume":"103","author":"Dugave","year":"2003","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jpba.2022.114862_bib27","unstructured":"G. Fu, F. He, W. Zhang, Method for synthesizing Milbemycin oxime. United States Patent US9598429B2, 2015."},{"key":"10.1016\/j.jpba.2022.114862_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2011.12.030","article-title":"Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H\/D exchange, and NMR","volume":"63","author":"Awasthi","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.114862_bib29","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1021\/jo00280a052","article-title":"Reinvestigation of the mechanism of the acid-catalyzed epimerization of reserpine to isoreserpine","volume":"54","author":"Zhang","year":"1989","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2022.114862_bib30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1021\/np050106d","article-title":"The epimerization of sesamin and asarinin","volume":"68","author":"Li","year":"2005","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.jpba.2022.114862_bib31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jps.2600810718","article-title":"A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues","volume":"81","author":"Fassberg","year":"1992","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2022.114862_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF02678811","article-title":"Reaction of oxygen and unsaturated fatty acids","volume":"61","author":"Gunstone","year":"1984","journal-title":"J. Am. Oil Chem. Soc."},{"key":"10.1016\/j.jpba.2022.114862_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0009-3084(87)90045-4","article-title":"Secondary products of lipid oxidation","volume":"44","author":"Frankel","year":"1987","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jpba.2022.114862_bib34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.7164\/antibiotics.47.812","article-title":"Milbemycin derivatives: epoxidation of milbemycins","volume":"47","author":"Naito","year":"1994","journal-title":"J. Antibiot."},{"key":"10.1016\/j.jpba.2022.114862_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/cr60305a004","article-title":"Photochemistry of the carbon-nitrogen double bond","volume":"77","author":"Padwa","year":"1977","journal-title":"Chem. Rev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522002837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522002837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:22:11Z","timestamp":1760001731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S0731708522002837"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114862","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural elucidation of major degradation products of milbemycin oxime drug substance using LC-MS and NMR","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114862"}}